A patient-like swine model of gastrointestinal fibrotic strictures for advancing therapeutics
Abstract Gastrointestinal (GI) strictures are difficult to treat in a variety of disease processes. Currently, there are no Food and Drug Administration (FDA) approved drugs for fibrosis in the GI tract. One of the limitations to developing anti-fibrotic drugs has been the lack of a reproducible, re...
Main Authors: | Ling Li, Mohamad I. Itani, Kevan J. Salimian, Yue Li, Olaya Brewer Gutierrez, Haijie Hu, George Fayad, Jean A. Donet, Min Kyung Joo, Laura M. Ensign, Vivek Kumbhari, Florin M. Selaru |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-06-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-92628-8 |
Similar Items
-
Differentiation of fibrotic and inflammatory component of Crohn’s disease-associated strictures
by: Jordi Rimola, et al.
Published: (2020-04-01) -
EUS-guided recanalization of complete gastrointestinal strictures
by: Miguel Martínez-Guillén, et al. -
Transurethral resection of fibrotic scar tissue combined with temporary urethral stent placement for patients with in anterior urethral stricture
by: Cheol Yong Yoon, et al.
Published: (2014-08-01) -
Can Conventional and Diffusion-Weighted MR Enterography Biomarkers Differentiate Inflammatory from Fibrotic Strictures in Crohn’s Disease?
by: Pietro Valerio Foti, et al.
Published: (2021-03-01) -
Rapamycin is Effective for Upper but not for Lower Gastrointestinal Crohn’s Disease-Related Stricture: A Pilot Study
by: Min Zhong, et al.
Published: (2021-02-01)